Literature DB >> 22825731

Clinical features of polymyalgia rheumatica and giant cell arteritis.

Carlo Salvarani1, Nicolò Pipitone, Annibale Versari, Gene G Hunder.   

Abstract

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory diseases that typically affect white individuals >50 years. Women are affected ∼2-3 times more often than men. PMR and GCA occur together more frequently than expected by chance. The main symptoms of PMR are pain and stiffness in the shoulders, and often in the neck and pelvic girdle. Imaging studies reveal inflammation of joints and bursae of the affected areas. GCA is a large-vessel and medium-vessel arteritis predominantly involving the branches of the aortic arch. The typical clinical manifestations of GCA are new headache, jaw claudication and visual loss. PMR and GCA usually remit within 6 months to 2 years from disease onset. Some patients, however, have a relapsing course and might require long-standing treatment. Diagnosis of PMR and GCA is based on clinical features and elevated levels of inflammatory markers. Temporal artery biopsy remains the gold standard to support the diagnosis of GCA; imaging studies are useful to delineate large-vessel involvement in GCA. Glucocorticoids remain the cornerstone of treatment of both PMR and GCA, but patients with GCA require higher doses. Synthetic immunosuppressive drugs also have a role in disease management, whereas the role of biologic agents is currently unclear.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825731     DOI: 10.1038/nrrheum.2012.97

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  147 in total

1.  Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis.

Authors:  V Kyle; E P Wraight; B L Hazleman
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

2.  Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease.

Authors:  A D Wagner; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Giant cell arteritis in Asians: a comparative study.

Authors:  Luciano S Pereira; Michael K Yoon; Thomas N Hwang; Jenny E Hong; Kathyrn Ray; Travis Porco; Timothy J McCulley
Journal:  Br J Ophthalmol       Date:  2010-06-28       Impact factor: 4.638

4.  Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.

Authors:  Michael S Lee; Scott D Smith; Anat Galor; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-10

5.  The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease.

Authors:  Martin A Walter; Ralph A Melzer; Christian Schindler; Jan Müller-Brand; Alan Tyndall; Egbert U Nitzsche
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-04       Impact factor: 9.236

6.  Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica.

Authors:  M Lopez-Hoyos; C Ruiz de Alegria; R Blanco; J Crespo; M Peña; V Rodriguez-Valverde; V M Martinez-Taboada
Journal:  Rheumatology (Oxford)       Date:  2004-02-17       Impact factor: 7.580

7.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Authors:  J Hernández-Rodríguez; M Segarra; C Vilardell; M Sánchez; A García-Martínez; M J Esteban; C Queralt; J M Grau; A Urbano-Márquez; A Palacín; D Colomer; M C Cid
Journal:  Rheumatology (Oxford)       Date:  2003-12-16       Impact factor: 7.580

8.  Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.

Authors:  José Hernández-Rodríguez; Marta Segarra; Carme Vilardell; Montse Sánchez; Ana García-Martínez; María-José Esteban; Josep M Grau; Alvaro Urbano-Márquez; Dolors Colomer; Hynda K Kleinman; Maria C Cid
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

9.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15

10.  PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis.

Authors:  Carlo Salvarani; Bruno Casali; Enrico Farnetti; Nicolò Pipitone; Debora Formisano; Davide Nicoli; PierLuigi Macchioni; Luca Cimino; GianLuigi Bajocchi; Maria Grazia Catanoso; Giovanna Restuccia; Alessandra Ghinoi; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2007-10
View more
  34 in total

Review 1.  The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist.

Authors:  Sara Monti; Alberto Floris; Cristina Ponte; Wolfgang A Schmidt; Andreas P Diamantopoulos; Claudio Pereira; Jennifer Piper; Raashid Luqmani
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

Review 2.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Comment on: FDG PET in the early diagnosis of large-vessel vasculitis.

Authors:  Zdeněk Rehák; Petr Szturz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

Review 4.  Giant cell arteritis: ophthalmic manifestations of a systemic disease.

Authors:  Elisabeth De Smit; Eoin O'Sullivan; David A Mackey; Alex W Hewitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-05       Impact factor: 3.117

Review 5.  Orbital Vasculitides-Differential Diagnosis.

Authors:  Gabriela M Espinoza; Jessica L Liu
Journal:  Curr Rheumatol Rep       Date:  2019-09-05       Impact factor: 4.592

Review 6.  Clinical practice. Giant-cell arteritis and polymyalgia rheumatica.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  N Engl J Med       Date:  2014-07-03       Impact factor: 91.245

7.  Early onset polymyalgia rheumatica: two rare cases under age of 50.

Authors:  Jinyoung Park; Duk Hyun Sung
Journal:  Skeletal Radiol       Date:  2017-03-21       Impact factor: 2.199

8.  The process from symptom onset to rheumatology clinic in polymyalgia rheumatica.

Authors:  Ediz Dalkılıç; Ayşe Nur Tufan; Emre Hafızoğlu; Merve Hafızoğlu; Fatih Tufan; Ferhat Oksuz; Yavuz Pehlivan; Mustafa Yurtkuran
Journal:  Rheumatol Int       Date:  2014-05-11       Impact factor: 2.631

9.  Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.

Authors:  Bryant R England; Ted R Mikuls; Fenglong Xie; Shuo Yang; Lang Chen; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2017-11-09       Impact factor: 10.995

10.  Giant Cell Arteritis: From Pathogenesis to Therapeutic Management.

Authors:  Ryu Watanabe; Jörg J Goronzy; Gerald Berry; Y Joyce Liao; Cornelia M Weyand
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.